Compound separated from folium artemisiae argyi as well as preparation method and application thereof

Abstract

The invention belongs to the field of antitumor drugs, and relates to a compound separated from folium artemisiae argyi and a preparation method and application thereof. The compound 1-7 separated from the folium artemisiae argyi provided by the invention has the following structural formula: # imgabs0 #, and the compound 1-7 separated from the folium artemisiae argyi has an inhibition effect on various cancer cells, can effectively inhibit the growth of tumor cells under the condition that the concentration is 40 mu M, and has a good practical application value.

Description

[0001] This application is a divisional application of the patent application with the application date of July 26, 2024, application number 202411015680.4, and invention name “Compounds isolated from mugwort leaves, preparation methods and applications thereof”. Technical Field

[0002] The invention belongs to the field of anti-tumor drugs, and in particular relates to a compound separated from mugwort leaves, a preparation method and an application thereof. Background Art

[0003] The statements in this section merely provide background information related to the present invention and do not necessarily constitute prior art.

[0004] Ovarian cancer (OC) is one of the three major malignant tumors of the female reproductive system, accounting for 2.1% of all cancers. The recurrence rate and mortality rate of ovarian cancer rank first among female reproductive tract malignancies. Cervical cancer (CC), also known as cervical cancer, is one of the most common gynecological malignancies and the fourth leading cause of death from malignant tumors in women. Although significant progress has been made in the treatment of ovarian and cervical cancers such as surgery, radiotherapy, and chemotherapy, the incidence of ovarian and cervical cancers in young women continues to increase, seriously threatening women's life and health. Therefore, finding new and effective anti-tumor drugs is one of the research focuses in the field of medicine today. Related studies have found that structural compounds such as sesquiterpenes and flavonoids have different biological activities, such as anti-tumor, anti-inflammatory, anti-malarial, and antibacterial pharmacological effects, and are a group of effective, low-toxic natural small molecules.

[0005] Artemisia argyi Lévl. et. Vant. is a plant of the genus Artemisia in the Asteraceae family. Qi mugwort is a renowned traditional Chinese medicinal herb. Li Shizhen noted in his Compendium of Materia Medica, "In modern times, the mugwort from Tangyin is called Northern mugwort, while the mugwort from Siming is called Sea mugwort. Since the Chenghua period, the mugwort from Qizhou has been considered superior, used in prescriptions and highly valued throughout the country, hence the name Qi mugwort." Research has found that Qi mugwort contains a variety of chemical components, including terpenes, flavonoids, phenolic acids, polysaccharides, and coumarins. Terpenes, in particular, possess significant physiological activity and medicinal value.

[0006] However, there are few studies on the isolation of compounds from Artemisia argyi for the prevention or treatment of tumor-related diseases. Summary of the Invention

[0007] In order to solve the above problems, the present invention provides a compound separated from Artemisia argyi and a preparation method thereof and an application thereof in the preparation of a method for preventing or treating tumor-related diseases.

[0008] In order to achieve the above object, the present invention adopts the following technical solutions:

[0009] The first aspect of the present invention provides a compound isolated from Artemisia argyi, selected from compounds having the following structural formula:

[0010]

[0011] A second aspect of the present invention provides a method for preparing the compound isolated from Artemisia argyi, comprising:

[0012] Heat and extract the mugwort leaves with 60% v / v-80% v / v ethanol solution, and concentrate the extract to obtain a crude extract;

[0013] The crude extract was dissolved in water, extracted with petroleum ether and ethyl acetate in sequence, and the ethyl acetate extract was collected and concentrated to obtain a crude extract;

[0014] The crude extract is separated and purified by column chromatography and high performance liquid chromatography to obtain a compound represented by any one of formulas 1-7.

[0015] In some embodiments, the heating extraction temperature is 55-65° C., and the heating extraction time is 8-12 hours;

[0016] In some embodiments, the heating extraction is performed 2-4 times.

[0017] In some embodiments, the solid-to-liquid ratio of the mugwort leaf and the ethanol solution is 1:14-20, preferably 1:17.

[0018] Preferably, the concentration of the ethanol solution is 70% v / v.

[0019] In some embodiments, the column chromatography uses one or two of normal phase silica gel column chromatography, reverse phase D101 macroporous resin column chromatography and gel column chromatography.

[0020] In some embodiments, the elution system of the column chromatography comprises methanol, dichloromethane-methanol, petroleum ether-ethyl acetate or methanol-water.

[0021] In some embodiments, the specific method of column chromatography is as follows: first, the ethyl acetate extract is passed through a normal phase silica gel column chromatography, and then a dichloromethane-methanol system is used for gradient elution at 100:0→0:100, and the gradient eluates of each gradient are collected and combined to obtain 7 components Fr.1-7, namely Fr.1, Fr.2, Fr.3, Fr.4, Fr.5, Fr.6, and Fr.7;

[0022] Fr.6 was subjected to silica gel column chromatography using a dichloromethane-methanol system with a gradient elution ratio of 100:0→0:100 to obtain six fractions, Fr.6-1 to Fr.6-6. Fr.6-5 was separated by gel column chromatography to obtain five fractions, Fr.6-5-1 to Fr.6-5-5. Fr.6-5-1 was purified by preparative HPLC to obtain the compound shown in Formula 1.

[0023] Alternatively, Fr.7 was subjected to silica gel column chromatography using a dichloromethane-methanol system with a gradient elution ratio of 100:0→0:100 to obtain five fractions Fr.7-1 to Fr.7-5;

[0024] Fr.7-1 was separated by gel column chromatography to obtain three fractions, Fr.7-1-1 to Fr.7-1-3. Fr.7-1-1 was recrystallized to obtain the compound shown in Formula 2.

[0025] Alternatively, Fr.7-1-2 is subjected to silica gel column chromatography and eluted with petroleum ether-ethyl acetate to obtain the compound shown in Formula 3;

[0026] Alternatively, Fr.7-1-3 is purified by HPLC preparative chromatography to obtain the compound shown in Formula 4;

[0027] Alternatively, after Fr.7-2 is subjected to gel column chromatography to remove the pigment, it is subjected to silica gel column chromatography and eluted with a petroleum ether-ethyl acetate system at a gradient of 7:1→1:1 to obtain three fractions Fr.7-2-1 to Fr.7-2-3;

[0028] Fr.7-2-1 was purified by HPLC preparative chromatography to obtain the compound represented by formula 5-7.

[0029] In some embodiments, the high performance liquid chromatography uses a reverse phase C18 column, the elution system is methanol-water or acetonitrile-water, the flow rate is 2-3 mL / min, the column temperature is 20-30°C, the injection volume per time is 20-100 μL, and an ultraviolet detector is used with detection wavelengths of 210 nm and 254 nm.

[0030] The third aspect of the present invention provides the use of the above-mentioned compound or the compound prepared by the above-mentioned method in the preparation of a drug for preventing or treating tumor-related diseases.

[0031] In some embodiments, the tumor includes: ovarian cancer, cervical cancer;

[0032] In some embodiments, the tumor cells include human ovarian cancer A2780 cells, human ovarian cancer SKOV3 cells, human cervical cancer C-33A cells, and human cervical squamous cell carcinoma SiHa cells.

[0033] Beneficial effects of the present invention

[0034] (1) The present invention provides seven new compounds isolated from Artemisia argyi: 5-hydroxymellein, artecanin, 3-O-methyl-iso-secotanapartholide, 3-methoxytanapartholide, canin, Artanomalide C, and guaianolide, whose structures are shown in Formulas 1-7, respectively. These compounds fill the gaps in the prior art and further expand the new applications of Artemisia argyi.

[0035] (2) The preparation method of the compound provided by the present invention is simple to operate and has good stability; the raw materials are readily available, easy to operate, high in yield, and suitable for industrial production.

[0036] (3) The compound isolated from mugwort provided by the present invention effectively inhibits the growth of ovarian cancer and cervical cancer cells at 40 μM and can be used to prepare anti-tumor drugs.

[0037] Advantages of additional aspects of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] The accompanying drawings, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their description are used to explain the present invention and do not constitute improper limitations on the present invention.

[0039] Figure 1 For Example 2 Compound 1 1 H-NMR spectrum.

[0040] Figure 2 For Example 2 Compound 1 13 C-NMR spectrum.

[0041] Figure 3 For Example 2 Compound 2 13 C-NMR spectrum.

[0042] Figure 4 For Example 2 Compound 3 1 H-NMR spectrum.

[0043] Figure 5 For Example 2 Compound 3 13 C-NMR spectrum.

[0044] Figure 6 For Example 2 Compound 4 13 H-NMR spectrum.

[0045] Figure 7 For Example 2 Compound 413 C-NMR spectrum.

[0046] Figure 8 For Example 2 Compound 5 1 H-NMR spectrum.

[0047] Figure 9 For Example 2 Compound 5 13 C-NMR spectrum.

[0048] Figure 10 For Example 2 Compound 6 1 H-NMR spectrum.

[0049] Figure 11 For Example 2 Compound 6 13 C-NMR spectrum.

[0050] Figure 12 For Example 2 Compound 7 13 C-NMR spectrum. DETAILED DESCRIPTION

[0051] It should be noted that the following detailed descriptions are exemplary and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0052] The present invention will be further described in detail below with reference to specific embodiments. It should be noted that the specific embodiments are intended to explain the present invention rather than to limit it.

[0053] Example 1

[0054] Preparation of compounds

[0055] (1) After washing and drying the fresh mugwort leaves, they were heated and extracted twice at 60°C with 70% ethanol (solid-to-liquid ratio of 1:17). The filtrates were combined and the extracts were concentrated to obtain the crude extract.

[0056] (2) After the crude extract is fully dissolved in water, it is extracted six times with petroleum ether and ethyl acetate in a volume ratio of 1:1 between the crude extract aqueous solution and the extractant, and the ethyl acetate extracts are combined and concentrated to obtain a crude extract (i.e., the crude extract aqueous solution is first extracted multiple times with petroleum ether to remove low-polarity components; then the crude extract aqueous solution is extracted multiple times with ethyl acetate, and the ethyl acetate extracts are collected);

[0057] (3) The crude fraction extracted with ethyl acetate was subjected to normal phase silica gel (200-300 mesh) column chromatography with a dichloromethane-methanol system for gradient elution at a ratio of 100:0, 100:1, 80:1, 70:1, 50:1, 30:1, 20:1, 5:1, and 0:100. The fraction was divided into 7 fractions (Fr. 1 to 7) after TLC analysis.

[0058] Fr.6 was purified by silica gel column chromatography (200-300 mesh) using a gradient elution of dichloromethane:methanol (100:0→0:100) to obtain six fractions, Fr.6-1 to Fr.6-6. Fr.6-5 was separated by gel column chromatography (dichloromethane:methanol 1:1) to obtain five fractions, Fr.6-5-1 to Fr.6-5-5. Fr.6-5-1 was purified by preparative HPLC chromatography (methanol:water = 27:73) to obtain compound 1.

[0059] Fr.7 was chromatographed on a silica gel column (200-300 mesh) using a gradient elution of dichloromethane:methanol (100:0→0:100) to obtain five fractions, Fr.7-1 to Fr.7-5;

[0060] Fr.7-1 was separated by gel column chromatography (dichloromethane: methanol 1:1) to obtain three fractions Fr.7-1-1 to Fr.7-1-3. Fr.7-1-1 was recrystallized to obtain compound 2; Fr.7-1-2 was purified by silica gel column chromatography (300-400 mesh) and eluted with petroleum ether: ethyl acetate (3:1) to obtain compound 3; Fr.7-1-3 was purified by HPLC preparative chromatography (acetonitrile: water = 30:70) to obtain compound 4.

[0061] After the pigment of Fr.7-2 was removed by gel column chromatography (dichloromethane: methanol 1:1), it was then eluted by silica gel column chromatography (300-400 mesh) with a gradient elution of petroleum ether: ethyl acetate (7:1→1:1) to obtain three fractions Fr.7-2-1 to Fr.7-2-3; Fr.7-2-1 was purified by preparative HPLC chromatography (methanol: water = 45:55) to obtain compounds 5, 6, and 7.

[0062] Example 2

[0063] Compound structure identification

[0064] After NMR identification of all compounds, the properties and spectral data of the obtained compounds are as follows:

[0065] Compound 1: 5-hydroxymellein, colorless crystals, molecular formula: C 10 H 10O4. 1H-NMR (600MHz, Pyr) δ: 7.01 (1H, d, J = 9.0Hz, H-6), 6.69 (1H, d, J = 8.7Hz, H-7), 4. 65(1H,m,H-3),3.39(1H,dd,J=3.4,16.8Hz,H-4b),2.71(1H,m,H-4a),1.39(3H,s,H- 9); 13C-NMR (126 MHz, Pyr) δ: 171.53 (C-1), 156.49 (C-8), 147.91 (C-5), 126.39 (C-10), 125.53 (C-6), 116.95 (C-7), 110.06 (C-11), 77.33 (C-3), 29.95 (C-4), 21.69 (C-9). The above data were consistent with those reported in the literature, and thus compound 1 was identified as 5-hydroxymellein.

[0066] Compound 2: artecanin, a colorless oil with the molecular formula C 15 H 18 O5. 1H-NMR (600MHz, CDCl3) δ: 6.21 (1H, d, J = 3.5Hz, H-13a), 5.38 (1H, d, J = 3.0Hz, H-13b), 4.47 (1H, dd, J = 10.3, 11.5Hz, H-13b), 3.66 (1H, br s,H-2),3.54(1H,br s, H-3), 1.64 (3H, s, H-15), 1.24 (3H, s, H-14); 13C-NMR (125 MHz, CDCl3) δ: 169.7 (C-12), 141.7 (C-11), 118.8 (C-13), 80.8 (C-6), 79.1 (C-1), 73.3 (C-4), 72.3 (C-10), 58.6 (C-2), 58.5 (C-3), 50.3 (C-7), 43.5 (C-5), 33.9 (C-9), 27.5 (C-14), 24.4 (C-8), 19.8 (C-15). The above data were consistent with those reported in the literature, so the compound 2 was identified as artecanin.

[0067] Compound 3: 3-O-methyl-iso-secotanapartholide, colorless oil, molecular formula: C 16 H 20O5. 1H-NMR (600MHz, CD3OD) δ: 6.25 (1H, d, J = 2.9 Hz, H-13), 5.76 (1H, d, J = 2.6 Hz, H-13'), 5.09 (1H, d, J = 5.5 Hz, H-6), 4.40 (3H, s, H-16), 3. 19(1H,m,H-3),3.11(1H,m,H-7),2.70(1H,dd,J=7.2,19.0Hz,H-3),2.6(1H,m,H-9),2.45(1H,m,H-2),2.13(1H,s,H-14),2.05(1H,s,H-15 ),1.98(1H,m,H-8');13C-NMR(125MHz,CD3OD)δ:210.30(C-10),205.02(C-1),178.44(C-4),172.71(C-12),140.66(C-5),140.39(C-11),122.77(C-13),77.62(C-3),77.74(C-6),54.59(C-16),43.65(C-7),40.52(C-2),38.30(C-9),31.97(C-14),29.84(C-8),14.16(C-15). The above data were consistent with those reported in the literature, so the compound 3 was identified as 3-O-methyl-iso-secotanapartholide.

[0068] Compound 4: 3-methoxytanapartholide, colorless oil, molecular formula C 16 H 20O5. 1H-NMR (600MHz, CDCl3) δ: 6.35 (1H, d, J = 2.6Hz, H-13), 5.66 (1H, d, J = 2.6Hz, H-13'), 4.97 (1H, d, J = 5.0Hz, H-6), 4.30 (1H, br d,J=6.0Hz,H-3),3.40(3H,s,H-16),3.05(1,m,H-7),2.69(1H,dd,J=6.0,18.0Hz,H-3),2.5(1H,m,H-9),2 .32(1H,dd,J=2.2,18.0Hz,H-2),2.21(1H,s,H-14),2.15(1H,s,H-15),1.8(1H,m,H-8');13C-NMR(125MHz, CDCl3)δ:205(C-1),202.2(C-10),170.2(C-12),138.6(C-11),129.6(C-5),126.4(C-4),121.6(C-13),81.4(C-6),75.2(C-3),58.2(C-16),42.2(C-7),40.1(C-9),38.7(C-2),28.9(C-14),28.7(C-8),13.7(C-15). The above data are consistent with those reported in the literature, so compound 4 is identified as 3-methoxytanapartholide.

[0069] Compound 5: Canin, colorless oil, molecular formula C 15 H 18O5. 1H-NMR (600MHz, CDCl3) δ: 6.21 (1H, d, J = 3.0Hz, H-13b), 5.49 (1H, d, J = 3.0Hz, H-13a), 4.34 (1H, dd, J = 9.5, 11.5Hz, 4.07 (1H, br s, H-3), 3.70 (1H, br s,H-2),3.45(1H,m,H-7),2.63(1H,d,J=11.5Hz,H-5),2.33(1H,m,H-8b),2.10(1H,m,H-8a),2.05(1H,m, H-9b),1.84(1H,m,H-9a),1.57(3H,s,H-15),1.27(3H,s,H-14);13C-NMR(125MHz,CDCl3)d:169.4(C-12) ,139.3(C-11),120.0(C-13),83.3(C-4),79.8(C-6),73.3(C-1),72.2(C-10),64.6(C-2),64.3(C-3),57.8(C-5),45.0(C-7),35.0(C-9),26.5(C-14),23.5(C-8),22.1(C-15). The above data are consistent with those reported in the literature, so compound 5 is identified as Canin.

[0070] Compound 6: artanomalide C, colorless oil, molecular formula C 15 H 18 O5. 1H-NMR (600MHz, CDCl3) δ: 6.21 (2H, d, J = 3.5Hz, H-13), 6.06 (1H, d, J = 1.5Hz, C-3), 5.49 (2H, d, J = 2.9Hz, H-13), 4 .41(1H,d,J=9.5Hz,H-5),3.41(1H,m,H-7),2.65(1H,s,H-1),2.29(3H,d,J=1.5Hz,H-15),1.8(2H,m,H-8),1.60(3H ,s,H-14); 13C-NMR (125 MHz,CDCl3)δ:203.8(C-2),177.8(C-4),169.5(C-12),139.1(C-11),131.7(C-3),120.1(C-13),86.0(C-6),82.4(C-5),71.6(C-10),68.0(C-1),41.0(C-7),38.6(C-9),32.7(C-14),22.5(C-8),16.2(C-15). The above data were consistent with those reported in the literature, so compound 6 was identified as artanomalide C.

[0071] Compound 7: guaianolide, colorless oil, molecular formula is C14H17ClO5. 1H-NMR (600MHz, CDCl3) δ: 6.19 (1H, d, J = 3.6 Hz, H-13a), 5.46 (1H, d, J = 3.4 Hz, H-13b), 4.38 (1H, dd, J = 9.6, 11.0 Hz, H-6), 4.10 (1H, d, J = 0.8 Hz, H-4), 3.86 (1H, d, J = 0.8 Hz, H-2), 3.58 (1H, m, H-7), 3.22 (1H, br s,4-OH),2.81(1H,d,J=11Hz,H-5),2.32(1H,m,H-8a),1.91(1H,m,H-9a),1.88(1H,m,H -9b),1.62(1H,m,H-8b),1.57(3H,s,H-14),1.23(3H,s,H-15); 13C-NMR(125MHz, CDCl3) δ: 170.5(C-12), 140.5(C-11), 80.0(C-4), 78.5(C-6), 73.0(C-1), 72.0(C-0), 64.0(C-3), 63.5(C-2), 50.0(C-5), 43.5(C-7), 33.5(C-9), 28.0(C-14), 24.0(C-15), 22.5(C-8). The above data are consistent with those reported in the literature, so compound 7 was identified as guaianolide.

[0072] Example 3

[0073] Antitumor activity experiment

[0074] Experimental Method: Compounds 1-7 obtained in Example 2 and the positive drug (paclitaxel) were prepared in DMSO to a 50 mM stock solution and stored at -20°C. The blank wells contained no cells and the test sample, the control wells contained cells but no test sample, and the test wells contained cells and the test sample. The CCK8 assay was used to determine the inhibitory effect of the samples on ovarian and cervical cancer cells, with three replicates set up for each sample concentration.

[0075] Specific operation steps: human ovarian cancer A2780 cells (purchased from Haixing Biotechnology Co., Ltd.) were cultured with RPMI-1640 complete medium (10% FBS, 1% penicillin, 1% streptomycin); human ovarian cancer SKOV3 cells (purchased from Wuhan Punosai Company) were cultured with McCoy's A complete medium (10% FBS, 1% penicillin, 1% streptomycin); human cervical cancer C-33A cells (purchased from Haixing Biotechnology Co., Ltd.) were cultured with MEM complete medium (10% FBS, 1% penicillin, 1% streptomycin); human cervical squamous cell carcinoma SiHa (purchased from Haixing Biotechnology Co., Ltd.) were cultured with DMEM complete medium (10% FBS, 1% penicillin, 1% streptomycin).

[0076] The cells were cultured in a constant temperature incubator at 37°C and 5% CO2. A2780 cells cultured to the logarithmic growth phase were plated at 5×10 3 100 μL of cell suspension was evenly plated into a 96-well plate and cultured for 24 hours until cells adhered and grew. Then, the test sample was diluted with 100 μL of drug-containing culture medium at a concentration of 40 μM, and the positive drug was diluted with 200 μL of drug-containing culture medium at a concentration of 20 μM. The medium was then changed for drug administration. After 24 hours of drug administration, the supernatant was discarded and 100 μL of culture medium containing 10% CCK8 was added to each well. After 1.5-2.5 hours of incubation in an incubator, the absorbance at 450 nm was measured using a microplate reader.

[0077] A2780 cells, SKOV3 cells, C-33A cells, and SiHa cells were treated according to the above method, and the positive drug used was paclitaxel. The results are shown in Table 1.

[0078] Table 1 shows the inhibition results of compounds 1-7 on 4 tumor cell lines at 40 μM.

[0079] Table 1

[0080]

[0081] It can be seen from the data in Table 1 that compounds 1-7 have high inhibitory effects on ovarian cancer cells (A2780, SKOV3).

[0082] It can be seen that compound 1-7 can effectively inhibit the growth of tumor cells at a concentration of 40 μM.

[0083] Experimental Example 4

[0084] Antitumor activity experiment

[0085] Experimental method: The data in Example 3 were screened to select ovarian cancer A2780 and SKOV3 cells that were more sensitive to compounds 1-7. The CCK8 assay was used to detect the inhibition rate of the samples on ovarian cancer cells, with three replicates set for each sample concentration.

[0086] Specific operation steps: Human ovarian cancer A2780 cells (purchased from Haixing Biotechnology Co., Ltd.) were cultured in RPMI-1640 complete medium (10% FBS, 1% penicillin, 1% streptomycin); human ovarian cancer SKOV3 cells (purchased from Wuhan Punosai Company) were cultured in McCoy's A complete medium (10% FBS, 1% penicillin, 1% streptomycin). The cells were cultured in a constant temperature incubator at 37°C and 5% CO2. A2780 cells cultured to the logarithmic growth phase were plated at 5×10 cells per well. 3 100 μL of cell suspension was evenly plated into a 96-well plate and cultured for 24 hours until cells adhered to the plate. Then, 200 μL of drug-containing medium was added to each well at concentrations of (0.625, 1.25, 2.5, 5, 10, and 20 μM) for the test sample, and 200 μL of drug-containing medium was added to each well at a concentration of 10 μM for the positive drug. After 24 hours of drug administration, the supernatant was discarded, and 100 μL of medium containing 10% CCK8 was added to each well. After 1.5-2.5 hours of incubation in an incubator, the absorbance at 450 nm was measured using a microplate reader.

[0087] A2780 cells and SKOV3 cells were treated according to the above method. The positive drugs used were paclitaxel, IC 50 The results are shown in Table 2.

[0088] Table 2

[0089]

[0090] As shown in Table 2, compounds 1-7 have better inhibitory effects on ovarian cancer A2780 and SKOV3 cells.

[0091] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention.

Claims

1. A compound isolated from Artemisia argyi, characterized in that Selected from compounds having the following structural formula:

2. A method for preparing the compound isolated from Artemisia argyi according to claim 1, characterized in that: include: Heat and extract the mugwort leaves with 60% v / v-80% v / v ethanol solution, and concentrate the extract to obtain a crude extract; The crude extract was dissolved in water, extracted with petroleum ether and ethyl acetate in sequence, and the ethyl acetate extract was collected and concentrated to obtain a crude extract; The crude extract is separated and purified by column chromatography and high performance liquid chromatography to obtain a compound represented by any one of formulas 1-6.

3. The method for preparing the compound isolated from Folium Artemisiae Argyi according to claim 2, wherein: The heating extraction temperature is 55-65°C and the heating extraction time is 8-12h; Alternatively, the heating extraction is performed 2-4 times.

4. The method for preparing the compound isolated from Folium Artemisiae Argyi according to claim 2, wherein: The solid-to-liquid ratio of the mugwort leaf and ethanol is 1:14-20, or 1:17; Alternatively, the concentration of the ethanol solution is 70% v / v.

5. The method for preparing the compound isolated from Folium Artemisiae Argyi according to claim 2, wherein: The column chromatography adopts one or two of normal phase silica gel column chromatography, reverse phase D101 macroporous resin column chromatography and gel column chromatography.

6. The method for preparing the compound isolated from Folium Artemisiae Argyi according to claim 2, wherein: The elution system of the column chromatography includes methanol, dichloromethane-methanol, petroleum ether-ethyl acetate or methanol-water.

7. The method for preparing the compound isolated from Folium Artemisiae Argyi according to claim 2, wherein: The specific method of the column chromatography is as follows: first, the ethyl acetate extraction portion flows through normal phase silica gel column chromatography, and then a dichloromethane-methanol system is used for gradient elution at 100:0→0:100, and the gradient eluates of each gradient are collected and combined to obtain 7 components Fr.1-7, namely Fr.1, Fr.2, Fr.3, Fr.4, Fr.5, Fr.6, and Fr.7; Fr.6 was subjected to silica gel column chromatography using a dichloromethane-methanol system with a gradient elution ratio of 100:0→0:100 to obtain six fractions, Fr.6-1 to Fr.6-6. Fr.6-5 was separated by gel column chromatography to obtain five fractions, Fr.6-5-1 to Fr.6-5-5. Fr.6-5-1 was purified by preparative HPLC to obtain the compound shown in Formula 1. Alternatively, Fr.7 was subjected to silica gel column chromatography using a dichloromethane-methanol system with a gradient elution ratio of 100:0→0:100 to obtain five fractions Fr.7-1 to Fr.7-5; Fr.7-1 was separated by gel column chromatography to obtain three fractions, Fr.7-1-1 to Fr.7-1-3. Fr.7-1-1 was recrystallized to obtain the compound shown in Formula 2. Alternatively, Fr.7-1-2 is subjected to silica gel column chromatography and eluted with petroleum ether-ethyl acetate to obtain the compound shown in Formula 3; Alternatively, Fr.7-1-3 is purified by HPLC preparative chromatography to obtain the compound shown in Formula 4; Alternatively, after Fr.7-2 is subjected to gel column chromatography to remove the pigment, it is subjected to silica gel column chromatography and eluted with a petroleum ether-ethyl acetate system at a gradient of 7:1→1:1 to obtain three fractions Fr.7-2-1 to Fr.7-2-3; Fr.7-2-1 was purified by HPLC preparative chromatography to obtain the compound shown in Formula 5-6.

8. The method for preparing the compound isolated from Folium Artemisiae Argyi according to claim 2, wherein: High performance liquid chromatography uses a reverse phase C18 column, the elution system is methanol-water or acetonitrile-water, the flow rate is 2-3 mL / min, the column temperature is 20-30°C, the injection volume each time is 20-100 μL, and an ultraviolet detector is used with detection wavelengths of 210 nm and 254 nm.

9. Use of the compound according to claim 1 or the compound prepared by the method according to any one of claims 2 to 8 in the preparation of a medicament for preventing or treating tumor-related diseases.

10. The use according to claim 8, characterized in that The tumors include: ovarian cancer, cervical cancer; Alternatively, the tumor cells include human ovarian cancer A2780 cells, human ovarian cancer SKOV3 cells, human cervical cancer C-33A cells, and human cervical squamous cell carcinoma SiHa cells.

Images